HUMA · Humacyte, Inc. · Webcasts, Transcripts & Audio
$0.50
-0.02 (-4.12%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company will not have sufficient liquidity to fund its operations beyond one year from the issuance of these condensed consolidated financial statements if the Company is unable to generate sufficient cash flows from commercial sales on a timely basis and/or obtain additional capital. These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$154.82M
Shares
277.80M
Volume · Oct 5
6.45M
Avg daily vol (3M)
6.46M
Humacyte, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Humacyte, Inc. (HUMA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$
−$31.90M
'24 Q1
24-05-10
·
$
−$56.66M
'24 Q2
24-08-13
·
$
−$39.20M
'24 Q3
24-11-08
·
$
−$20.94M
'24 Q4
25-03-28
·
$517,000
$39.14M
'25 Q1
25-05-13
·
$301,000
−$37.66M
'25 Q2
25-08-11
·
$753,000
−$17.51M
'25 Q3
25-11-12
·
$467,000
−$24.80M
'25 Q4
26-03-27
▼4.3%
$495,000
−$17.62M
'26 Q1
26-04-28
LATEST
▲34.9%
$406,000
−$36.80M
'26 Q2
26-08-12
Earnings call
FY26 · Q2
2026-08-12
Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript
Confident tone
CTEV coronary program / IND
VO12 Phase III dialysis trial results
Supplemental BLA filing plans
Revenue
$406,000
▲ 34.9% YoY Diluted EPS
$-0.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Investor Update
Investor event
2026-04-28
Humacyte, Inc. (HUMA) April 2026 Investor Update
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-28
Humacyte, Inc. (HUMA) Q1 2026 Earnings Call Transcript
Positive tone
CTEV in CABG (coronary program)
CMS reimbursement and female dialysis population
Supplemental BLA in dialysis
Revenue
$495,000
▼ 4.3% YoY Diluted EPS
$-0.09
▼ 132.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-27
Humacyte, Inc. (HUMA) Q4 2025 Earnings Call Transcript
Positive tone
Symvess U.S. commercial launch
International expansion
Clinical data and publications
Revenue
$467,000*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript
Positive tone
Symvess commercial launch and sales growth
Dialysis access program (ATEV/V007)
VAC committee approvals and hospital access expansion
Revenue
$753,000
Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript
Positive tone
Symvess commercial launch and VAC approvals
V007 Phase III dialysis / ATEV
Coronary artery bypass (CABG) program
Revenue
$301,000
Diluted EPS
$-0.24
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript
Confident tone
Symvess commercial launch and VAC approvals
ATEV dialysis access program (V007, V012, sBLA)
Small-diameter ATEV / coronary bypass program
Revenue
$517,000
Diluted EPS
$0.28
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-28
Humacyte, Inc. (HUMA) Q4 2024 Earnings Call Transcript
Confident tone
Symvess commercial launch and hospital adoption
Small diameter ATEV for CABG
ATEV dialysis access (V007/V012)
Revenue
$*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Humacyte, Inc. (HUMA) Q3 2024 Earnings Call Transcript
Positive tone
FDA BLA review of ATEV in vascular trauma
Biovascular Pancreas (BVP) for Type 1 diabetes
V007 Phase 3 dialysis access results
Revenue
$
Diluted EPS
$-0.33
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Humacyte, Inc. (HUMA) Q2 2024 Earnings Call Transcript
Positive tone
ATEV Phase 3 V007 dialysis access results
FDA review delay for vascular trauma BLA
Advanced Peripheral Arterial Disease (PAD) program
Revenue
$
Diluted EPS
$-0.48
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-10
Humacyte, Inc. (HUMA) Q1 2024 Earnings Call Transcript
Confident tone
BLA Review and FDA Interaction
Reimbursement and Coding
Dialysis Access / V007 Trial
Revenue
$
Diluted EPS
$-0.29
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-22
Humacyte, Inc. (HUMA) Q4 2023 Earnings Call Transcript
Confident tone
BLA submission and FDA acceptance for vascular trauma
Clinical data superiority vs. synthetic grafts
Commercial preparation and launch readiness
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Humacyte, Inc. (HUMA) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.25
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Humacyte, Inc. (HUMA) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.22
▼ 162.9% YoY
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-12
Humacyte, Inc. (HUMA) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.36
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-24
Humacyte, Inc. (HUMA) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Humacyte, Inc. (HUMA) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.25
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-12
Humacyte, Inc. (HUMA) Q2 2022 Earnings Call Transcript
Diluted EPS
$0.35
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-13
Humacyte, Inc. (HUMA) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.19
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-29
Humacyte, Inc. (HUMA) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–20 of 20 webcasts